Skip to content
DataLookout
Menu

STARLiTNCT06574880

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 40 words
    • Primary completion pushed from Sep 1, 2026 to Jan 1, 2027
    • Secondary endpoints: details revised at 7 of 14 entries
  2. Notable Primary completion date: Mar 1, 2026 to Sep 1, 2026v8
  3. Notable Eligibility criteria expanded, about 33 words
    • Primary completion date: Sep 11, 2025 to Mar 1, 2026
    • Study completion date: Sep 11, 2026 to Mar 1, 2027
    v7
  4. Minor Start date changed from estimate of May 6, 2025 to May 13, 2025v6
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 1, 2025 to May 6, 2025
    • Site details revised
    v5
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Start date: Mar 11, 2025 to May 1, 2025v4
  2. Notable Start date: Sep 11, 2024 to Mar 11, 2025v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617
Timeframe: 4 weeks after final dose of treatment (treatment expected to last up to six months)
Phase II: Androgen deprivation therapy (ADT)-free survival
Timeframe: 3 years post treatment

Secondary (14)

PSA Progression Free Survival
Overall Survival (OS)
Prostate Cancer-specific Survival (PCSM)
Cumulative incidence of distant metastases
Time to any salvage therapy
Show 9 moreShow less
Change in Quality of life score as measured by EPIC-26
Change in Quality of life score as measured by XeQoLS
Change in Quality of life score as measured by FACT-RNT
Time-to-castration-resistant prostate cancer
Rate of participants with post treatment PSA in goal range
Incidence of acute toxicity
Incidence of late toxicity
Biochemical recurrence (BCR)
Proportion of participants with PSA50-RR

Arms and interventions

Lu-PSMA-617 + SBRTExperimental

* Lu-PSMA-617: 7.4GBq intravenous infusion once with cycle 1, followed by 7.4GBq cycle 2 that is delivered 6 weeks after SBRT , and potentially 7.4GBq cycle #3 delivered 6 weeks after cycle #2 pending dose escalation * Radiation therapy: 5 fractions to prostate and elective nodal irradiation, SBRT, delivered 6 weeks after cycle 1 of 177Lu-PSMA-617

Drugs: Lu-PSMA-617

Radiation: 5-fraction Stereotactic Body Radiation Therapy (SBRT)

Sites

1 site in 1 country

  • University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer CenterCleveland, Ohio, United States